Practical use of sevelamer in chronic kidney disease patients on dialysis in People’s Republic of China

@article{Meng2015PracticalUO,
  title={Practical use of sevelamer in chronic kidney disease patients on dialysis in People’s Republic of China},
  author={Lin Meng and B. Fu},
  journal={Therapeutics and Clinical Risk Management},
  year={2015},
  volume={11},
  pages={705 - 712}
}
  • Lin Meng, B. Fu
  • Published 2015
  • Medicine
  • Therapeutics and Clinical Risk Management
Hyperphosphatemia is a common complication of dialysis patients. Only 38.5% of Chinese dialysis patients met the Kidney Disease Outcomes Quality Initiative defined targets for serum phosphate. Sevelamer is a high molecular weight cationic hydrogel polymer that prevents absorption of dietary phosphate by binding it in the gastrointestinal tract. In Chinese trials, it was confirmed that sevelamer had better efficacy than calcium carbonate in terms of reducing the serum level of phosphorus and… Expand
Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China.
TLDR
Sevelamer is likely to be a cost-effective option in treating hyperphosphatemia among patients with end-stage renal disease in China compared with CBBs in the local context of China. Expand
Sevelamer reduces endothelial inflammatory response to advanced glycation end products
TLDR
The binding capacity of sevelamer to both AGEs and uremic serum in vitro was investigated to test this pharmaceutical effect as a potential vascular anti-inflammatory strategy and decreased both endothelial expression of RAGE and endothelial dysfunction biomarkers, induced by A GEs, and u Remic serum. Expand

References

SHOWING 1-10 OF 55 REFERENCES
Comparison of Sevelamer Hydrochloride and Sevelamer Carbonate: Risk of Metabolic Acidosis and Clinical Implications
TLDR
Both drugs appear to be equivalent in their abilities to lower serum phosphorus concentrations, however, as sevelamer carbonate does not decrease serum bicarbonate levels, it may be more appropriate for patients at risk for metabolic acidosis who require phosphate binders that do not contain calcium or aluminum. Expand
Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.
TLDR
Overall, sevelamer is a valuable option for the management of hyperphosphataemia in patients with ESRD on haemodialysis and was generally as well tolerated as calcium acetate or calcium carbonate treatment. Expand
Combination Therapy with Sevelamer Hydrochloride and Calcium Carbonate in Japanese Patients with Long‐Term Hemodialysis: Alternative Approach for Optimal Mineral Management
  • H. Ogata, F. Koiwa, K. Shishido, E. Kinugasa
  • Medicine
  • Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • 2005
TLDR
The results suggest that the therapeutic regimen is more tolerant and reduces Ca load in Japanese hemodialysis patients while avoiding hypocalcemia and the mitigated Ca overload could improve PTH hyposecretion in patients with adynamic bone disease, which is associated with soft tissue calcification and higher mortality in uremia. Expand
Efficacy of sevelamer carbonate on hyperphosphatemia patients undergoing maintenance hemodialysis
TLDR
Sevelamer carbonate can effectively reduce serum level of phosphorus and calcium-phosphorus product in MHD patients, and these levels decreased after two weeks of treatment. Expand
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.
TLDR
Compared with calcium-based phosphate binders, sevelamer is less likely to cause hypercalcemia, low levels of PTH, and progressive coronary and aortic calcification in hemodialysis patients. Expand
Mineral and bone disorder in Chinese dialysis patients: a multicenter study
TLDR
Age, dialysis patterns and region of residency were independently associated with hyperphosphatemia and status of MBD is sub-optimal among Chinese patients receiving dialysis. Expand
Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
  • N. Chen, Xiongfei Wu, +19 authors J. Neylan
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2014
TLDR
This study demonstrated that hyperphosphataemia developed quickly following the cessation of phosphate binders and remained persistently elevated in end-stage CKD in the placebo-treated group of Chinese haemodialysis patients. Expand
Sevelamer Hydrochloride Dose‐Dependent Increase in Prevalence of Severe Acidosis in Hemodialysis Patients: Analysis of Nationwide Statistical Survey in Japan
  • Y. Oka, M. Miyazaki, +6 authors F. Uno
  • Medicine
  • Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • 2014
TLDR
The results call for careful monitoring of serum bicarbonate level in hemodialysis patients treated with sevelamer hydrochloride. Expand
Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
  • V. Brandenburg, G. Schlieper, +10 authors M. Ketteler
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2010
TLDR
In haemodialysis patients, treatment with sevelamer over 8 weeks was associated with a delayed yet long-lasting increase in serum fetuin-A levels, and this work failed to detect a decrease in systemic inflammation and uraemic toxins. Expand
Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
TLDR
There is insufficient data to establish the comparative superiority of non-calcium-binding agents over calcium-containing phosphate binders for such important patient-level outcomes as all-cause mortality and cardiovascular end points, and suboptimal reporting of study methods to determine trial quality. Expand
...
1
2
3
4
5
...